Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Multiple Sclerosis

  Free Subscription


26.10.2026

1 Brain
2 J Neurol
1 Lancet
1 Lancet Neurol
4 Mult Scler
2 Neurology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Brain

  1. HUNT DPJ
    Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion.
    Brain. 2026 Oct 21:awag308. doi: 10.1093.
    PubMed        


    J Neurol

  2. BRAMOW S, Pontieri L, Heick A, Thormann A, et al
    Prediction of short-term and long-term responses to cladribine in relapsing-remitting multiple sclerosis: a Danish nationwide real-world study.
    J Neurol. 2026;273:676.
    PubMed         Abstract available

  3. BOURRE B, Guerrier O, Ayrignac X, Suchet L, et al
    DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naive patients with relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:679.
    PubMed         Abstract available


    Lancet

  4. WIENDL H, Bermel R, Airas L, Chitnis T, et al
    Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.
    Lancet. 2026 Oct 23:S0140-6736(26)02058-1. doi: 10.1016/S0140-6736(26)02058.
    PubMed         Abstract available


    Lancet Neurol

  5. JENSEN LT, Gold R, McVean G, Attfield KE, et al
    The clinical relevance of multiple sclerosis genetics: from susceptibility to disease severity and progression.
    Lancet Neurol. 2026 Oct 23:S1474-4422(26)00356.
    PubMed         Abstract available


    Mult Scler

  6. VALERO-HERNANDEZ E, Mathur J, Baker D, Liu IYH, et al
    Lymphocytosis as a biomarker for natalizumab treatment response in multiple sclerosis: The link with anti-drug antibodies.
    Mult Scler. 2026 Oct 17:13524585261495351. doi: 10.1177/13524585261495351.
    PubMed         Abstract available

  7. KWON S, Kim J, Chung YH, Kim B, et al
    Increased autoimmune disease burden before multiple sclerosis and neuromyelitis optica spectrum disorder diagnosis: A nationwide Korean cohort study.
    Mult Scler. 2026 Oct 17:13524585261494379. doi: 10.1177/13524585261494379.
    PubMed         Abstract available

  8. FREEDMAN DE, Oh J, Feinstein A
    Who declines neurocognitive testing? A cross-sectional study in people with multiple sclerosis.
    Mult Scler. 2026 Oct 17:13524585261491122. doi: 10.1177/13524585261491122.
    PubMed         Abstract available

  9. ROTSTEIN DL, Halani S, Vadas P, Marriott JJ, et al
    Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies.
    Mult Scler. 2026;32:1339-1342.
    PubMed         Abstract available


    Neurology

  10. PREZIOSA P, Meani A, Tedone N, Gattuso I, et al
    Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218641.
    PubMed        

  11. CORTESE R, Bianchi A, de Mauro A, Luchetti L, et al
    Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
    Neurology. 2026;107:e218673.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum